Monopar Therapeutics
MNPR Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$71.84
KIRA · Stoqly’s AI analyst, in plain words
- Monopar Therapeutics had $0.0M of revenue in fiscal 2025.
- Monopar Therapeutics lost $13.7M in fiscal 2025.
- Monopar Therapeutics returned $35.0M to shareholders in fiscal 2025.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$13.7M
Free cash flow
—
Operating margin
—
Monopar Therapeutics in 30 seconds · fiscal 2025
Does it make a profit?
−$13.7M
No. It lost money last year.
What Monopar Therapeutics does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Monopar Therapeutics
- CIK
- 0001645469
Monopar Therapeutics · MNPR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.4M | $0.0M | $0.0M |
| Revenue growth | −70.7% | −11.7% | 1,923.6% | −100.0% | — |
| Net interest income | $0.0M | $0.0M | $0.4M | — | — |
| Operating margin | −38,030.0% | −49,702.4% | −2,058.6% | — | — |
| Net income | −$9.1M | −$10.5M | −$8.4M | −$15.6M | −$13.7M |
| Net margin | −37,930.0% | −49,601.9% | −1,958.6% | — | — |
| Diluted EPS | −$0.73 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$7.3M | −$7.2M | −$7.9M | −$6.4M | −$12.2M |
| Share buybacks | — | — | — | $0.0M | $35.0M |
| Share count change | 13.8% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $20.3M | $20.4M | $13.8M | $91.3M | $123M |
| Shareholders' equity | $18.9M | $10.1M | $5.6M | $55.0M | $138M |
| Current ratio | 13.0x | 4.2x | 4.2x | 11.5x | 51.4x |
| Returns and quality | |||||
| Return on equity | −52.6% | −72.4% | −107.2% | −51.4% | −14.2% |
| Return on tangible equity | −48.1% | −104.2% | −150.4% | −28.3% | −10.0% |
| Piotroski F-score | 1 | — | — | — | — |
| Altman Z'' | 9.1 | −9.8 | −26.5 | 11.1 | 53.6 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$4.4M
6 insiders
Of sales under plans
92%
$4.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Monopar Therapeutics · MNPR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $71.84 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001645469). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.